1. Home
  2. BTQ vs MYGN Comparison

BTQ vs MYGN Comparison

Compare BTQ & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BTQ Technologies Corp.

BTQ

BTQ Technologies Corp.

BUY

Current Price

$2.01

Market Cap

394.2M

Sector

N/A

ML Signal

BUY

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.82

Market Cap

372.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTQ
MYGN
Founded
1983
1991
Country
Canada
United States
Employees
35
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
394.2M
372.1M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
BTQ
MYGN
Price
$2.01
$5.82
Analyst Decision
Strong Buy
Hold
Analyst Count
2
9
Target Price
★ $5.98
$4.11
AVG Volume (30 Days)
1.6M
★ 2.7M
Earning Date
11-13-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $771,400,000.00
Revenue This Year
$106.02
N/A
Revenue Next Year
$976.92
$5.47
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 2.33
52 Week Low
$1.82
$2.74
52 Week High
$10.20
$8.50

Technical Indicators

Market Signals
Indicator
BTQ
MYGN
Relative Strength Index (RSI) 29.33 74.13
Support Level N/A $5.57
Resistance Level $3.40 $6.34
Average True Range (ATR) 0.19 0.33
MACD -0.05 0.16
Stochastic Oscillator 12.01 92.25

Price Performance

Historical Comparison
BTQ
MYGN

About BTQ BTQ Technologies Corp.

BTQ Technologies Corp is engaged in the development of computer-based technology related to post-quantum cryptography, particularly as it applies to blockchain and related technologies, and their protection from the emerging security risk of quantum computing. The company derives revenue from Software licensing. Geographically, the company has a presence in Canada, Taiwan, Australia, and the United States.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: